• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

This Virus Infects Around 95 Percent Of Us – And Its Weak Spots Have Now Been Found

March 13, 2024 by Deborah Bloomfield

Epstein-Barr Virus (EBV) has no available vaccine or cure – but that may not be the case forever. New research has uncovered some of the virus’s vulnerabilities, opening the door to the possibility of targeted treatment.

You are probably infected with EBV. It’s overwhelmingly prevalent in the human population, estimated to have infected around 95 percent of us, yet most people would never know they had it. However, when it does decide to rear its head, it’s associated with some fairly nasty diseases including mononucleosis (sometimes called glandular fever), multiple sclerosis, and some cancers.  

Advertisement

A lot of effort has gone into developing a vaccine for EBV, but as of now there isn’t one available, and we also don’t have any specific treatments for the virus.

Despite how widespread it is, and how serious its effects can be, EBV was only discovered in 1964 by Dr Anthony Epstein –who recently passed away aged 102 – and his then-doctoral student Yvonne Barr. At the time, it was groundbreaking – no cancer-causing virus had ever been identified before. Since then, we’ve learned of others like the human papillomavirus (HPV), for which we even have a very effective vaccine. However, EBV is still stubbornly resistant to treatment.

Thanks to a new study, that could be about to change. Investigators at the National Institute of Allergy and Infectious Diseases (NIAID) examined a protein called gp42 which EBV uses to infect B cells, a type of white blood cell, in which the virus can sit quite happily for the remainder of a person’s life.

The team developed two monoclonal antibodies targeting gp42, called A10 and 4C12. The aim is to stop the protein from binding to or fusing with the B cells, preventing the virus from getting in there in the first place.

Advertisement

X-ray crystallography revealed that the two antibodies were interacting with two different sites on the gp42 protein. To investigate how this could impact EBV infection, the team performed experiments on mice using A10, 4C12, and several other antibodies. A10 came out on top: it almost completely blocked infection and none of the treated mice developed lymphoma, one of the cancers associated with EBV.

While still limited to mice for now, the results are promising. If further research shows a similar effect in humans, A10 could be a promising preventative option for people not yet infected with EBV. It could also be a game-changer for people with compromised immune systems, due to illness or transplant surgery for example. These individuals are at particular risk of severe disease caused by EBV, which can even be fatal.

Having identified the weak spots on the gp42 protein, scientists could also now go on to design vaccines that generate antibodies to one or both of the sites, giving the human immune system the chance to mount its own response against this ubiquitous threat.

The study is published in the journal Immunity.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Kroger expects smaller decline in same-store sales on grocery demand
  2. Libya presidency council head plans to hold October conference
  3. Cold Water Therapy: What Are The Benefits And Dangers Of Ice Baths, Wild Swimming And Freezing Showers?
  4. If Enceladus Or Europa Have Life It Might Be Easy To Find

Source Link: This Virus Infects Around 95 Percent Of Us – And Its Weak Spots Have Now Been Found

Filed Under: News

Primary Sidebar

  • Could This Be The Real Reason Humans Survived And Neanderthals Died Out?
  • Newly Discovered Snail Species Named After Studio Ghibli Co-Founder Is A Hairy Beauty
  • 2025 SC79 Is The Second-Fastest Asteroid Ever Found – And Only The Second Within Venus’ Orbit
  • When Red Devil Spiders Arrived On A New Island, Their Genome Dramatically Shrank In Half
  • Is This The World’s Oldest Story? Ancient Human Tale About The Seven Sisters May Be From 100,000 BCE
  • This Pill Is Actually A Tiny Printer That Repairs Internal Injuries Using Biocompatible Ink
  • “This Is Amazing”: Scientists Have Found Evidence Of A Long-Lost World Deep Within The Earth
  • From The Shiniest World To Lava And Eternal Darkness, These Are The Weirdest Known Planets
  • Do Sharks Have Bones?
  • The Zombie Awakens: A Volcano Is Showing “First Signs” Of Unrest After 700,000 Years Of Quiet
  • Two Of The World’s Biggest Earthquakes Seem To Be Synched Together
  • California Has A New State Snake, And It’s A 1.6-Meter-Long Giant
  • Experimental Nanoparticle “Super-Vaccines” Stop Breast, Pancreatic, And Skin Cancers In Their Tracks
  • New Nightmare Fuel Unlocked: Watch The First Known Capture Of A Shrew By A False Widow Spider
  • Peculiar Glow In The Milky Way Might Be Dark Matter Signature
  • “I Was Scared To Death”: Missouri’s Great Cobra Scare Of 1953 Was Eventually Solved After 35 Years
  • Two Spacecraft To Fly Through Comet 3I/ATLAS’s Ion Tail – Will They Be Able To Catch Something?
  • Pioneering Heavy Water Detection Suggests Earth’s Water Might Be Older Than The Sun
  • PhD Students’ Groundbreaking New Technique Rescues JWST’s Highest Resolution Data
  • Popcorn-Like Parasites And Weird Worms Among 14 New Species Discovered In The World’s Oceans
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version